arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

JUPITER NEUROSCIENCES, INC.

JUNS
$5.25 ▲ +5.17 (+6780.73%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
4 Visible periods
19 Metrics
Absolute Benchmarks
Price Chart
18
Health
Poor
Neutral Absolute basis
auto_awesome

Analytical Summary

On an absolute basis, JUPITER NEUROSCIENCES, INC. shows solid but mixed fundamentals, with Return on Invested Capital holding up well. Watch FCF / Net Income against typical quality thresholds. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $181.8M
Dividend Yield
Revenue Growth
Op. Margin
ROIC 384.2%
FCF / Share $-0.16
Trailing P/E
Price / Book
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

4-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$21.80K
Net Income Profit after all expenses
$-8.64M
↓ -254.4%
FCF / Share Free cash flow per share
$-0.16
↓ -15.1%

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

  • Return on Invested CapitalReturn on Invested Capital of 384.2% is excellent on an absolute basis (target > 10%)
warning

Bearish Risks

  • FCF / Net IncomeFCF / Net Income of 0.63x is weak on an absolute basis (target > 1x)

Health Breakdown

Cash Quality
18

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 4 years · 14 quarters